November 12, 2015Journal of Nuclear MedicineOpen Access

First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease

View Full Paper

Ask AI

Bookmark

Abstract

CXCR4-targeted radiotherapy with pentixather appears to be a promising novel treatment option in combination with cytotoxic chemotherapy and autologous stem cell transplantation, especially for patients with advanced multiple myeloma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Herrmann et al. (2015) studied this question.

synapsesocial.com/papers/69dae7c1e6ab964fb0836c22 https://doi.org/10.2967/jnumed.115.167361

View Full Paper

Ask AI

Bookmark

First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease

Abstract

Discussion

Cite This Study

First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease

Abstract

Discussion

Cite This Study

Keep reading

Keep reading